Blog posts

What is the future for the generics and biosimilars industry? Is there only one possible future or even different futures that manufacturers could face?

Switzerland and the UK have recently been categorised as third countries by the EU. This affects trade relations between EU producers and producers from the UK and Switzerland.

The European Medicines Agency finds a solution that allows performing GMP and GDP inspections from remote.

The introduction of the COVID-19 vaccine is becoming the biggest challenge for chemical supply chains in history.

Under the title: "La Ola - was that the "perfect" wave?" our management consultant Dr. Ralf Hess gave an interview to the UNIversalis newspaper.

What the EU must do to make the pan-European health system crisis-proof in the future.

Dr Ralf Hess, Dominik M. Aumer, Moritz Haucke and Dr Simon Schulz publish articles on drug shortages and their causes in RAPS.

Research into a drug against SARS-CoV-2 is giving small molecules a renaissance.

News on the harmonized standard ISO 15223.